[go: up one dir, main page]

MX2020008436A - Anticuerpos anti-alfa-sinucleina y metodos de uso. - Google Patents

Anticuerpos anti-alfa-sinucleina y metodos de uso.

Info

Publication number
MX2020008436A
MX2020008436A MX2020008436A MX2020008436A MX2020008436A MX 2020008436 A MX2020008436 A MX 2020008436A MX 2020008436 A MX2020008436 A MX 2020008436A MX 2020008436 A MX2020008436 A MX 2020008436A MX 2020008436 A MX2020008436 A MX 2020008436A
Authority
MX
Mexico
Prior art keywords
methods
alpha
synuclein antibodies
synuclein
antibodies
Prior art date
Application number
MX2020008436A
Other languages
English (en)
Inventor
Klaus Kaluza
Olaf Mundigl
Markus Britschgi
Sylwia Huber
Thomas Kremer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020008436A publication Critical patent/MX2020008436A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona anticuerpos anti-alfasinucleína humana y métodos de uso de los mismos.
MX2020008436A 2013-11-21 2016-04-29 Anticuerpos anti-alfa-sinucleina y metodos de uso. MX2020008436A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13193892 2013-11-21

Publications (1)

Publication Number Publication Date
MX2020008436A true MX2020008436A (es) 2020-09-25

Family

ID=49619846

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016005631A MX2016005631A (es) 2013-11-21 2014-11-18 Anticuerpos anti-alfa-sinucleina y metodos de uso.
MX2020002289A MX2020002289A (es) 2013-11-21 2016-04-29 Anticuerpos anti-alfa-sinucleina y metodos de uso.
MX2020008436A MX2020008436A (es) 2013-11-21 2016-04-29 Anticuerpos anti-alfa-sinucleina y metodos de uso.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016005631A MX2016005631A (es) 2013-11-21 2014-11-18 Anticuerpos anti-alfa-sinucleina y metodos de uso.
MX2020002289A MX2020002289A (es) 2013-11-21 2016-04-29 Anticuerpos anti-alfa-sinucleina y metodos de uso.

Country Status (25)

Country Link
US (5) US9493553B2 (es)
EP (2) EP3783020A1 (es)
JP (3) JP2017504566A (es)
KR (3) KR102399292B1 (es)
CN (3) CN111499742B (es)
AR (1) AR098465A1 (es)
AU (3) AU2014351996B2 (es)
CA (1) CA2924268C (es)
ES (1) ES2821904T3 (es)
HK (1) HK1220473A1 (es)
HR (1) HRP20201493T1 (es)
HU (1) HUE051982T2 (es)
IL (1) IL244495B (es)
LT (1) LT3071597T (es)
MX (3) MX2016005631A (es)
MY (1) MY176237A (es)
NZ (1) NZ717673A (es)
PL (1) PL3071597T3 (es)
PT (1) PT3071597T (es)
RS (1) RS60882B1 (es)
RU (2) RU2718990C1 (es)
SG (1) SG10202007189VA (es)
SI (1) SI3071597T1 (es)
TW (1) TW201609804A (es)
WO (1) WO2015075011A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121339A1 (en) 2014-02-14 2015-08-20 RUHR-UNIVERSITäT BOCHUM Biosensor for conformation and secondary structure analysis
AR105089A1 (es) * 2015-06-24 2017-09-06 Hoffmann La Roche ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
ES2908009T3 (es) 2015-06-24 2022-04-27 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad adaptada
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB2541003A (en) * 2015-08-05 2017-02-08 Kran Life Sciences Llp Neurodegenerative disorders
CN114014936A (zh) 2015-10-02 2022-02-08 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20250392A1 (es) 2016-06-02 2025-02-11 Medimmune Ltd Anticuerpos a la alfa-sinucleina y usos de los mismos
KR102593669B1 (ko) 2016-11-15 2023-10-25 하. 룬드벡 아크티에셀스카브 시누클레인병증의 치료를 위한 제제, 용도 및 방법
EP3324186B1 (en) 2016-11-21 2020-09-16 Ruhr-Universität Bochum Method for the preselection of drugs for protein misfolding diseases
EP3555127B1 (en) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
WO2018151821A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
EP3618870A4 (en) * 2017-05-01 2021-04-21 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST ALPHA-SYNUCLEIN FIBRILLES
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
WO2018237338A1 (en) * 2017-06-23 2018-12-27 Denali Therapeutics Inc. ANTI-ALPHA-SYNCUCIN ANTIBODIES AND METHODS OF USE
EP3672635A4 (en) 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
JP7212391B2 (ja) * 2017-12-14 2023-01-25 エービーエル バイオ インコーポレイテッド ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
GB201720970D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EP3752840A4 (en) * 2018-02-12 2022-08-10 The Scripps Research Institute PROCEDURES RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES
EP3833435A4 (en) * 2018-08-09 2022-05-11 F. Hoffmann-La Roche AG DETERMINATION OF PARKINSON'S DISEASE
BR112021006123A2 (pt) * 2018-10-19 2021-07-20 Janssen Vaccines & Prevention B.V. anticorpos anti-sinucleína
US11542322B2 (en) 2019-02-13 2023-01-03 Iowa State University Research Foundation, Inc. Nano-theranostics for Parkinson's disease
WO2021207613A1 (en) * 2020-04-10 2021-10-14 2Seventy Bio, Inc. Frb antibodies
BR112022021203A2 (pt) 2020-04-24 2022-12-06 Hoffmann La Roche Modulação de enzima e via com compostos sulfidrila e seus derivados
JP2022027513A (ja) 2020-07-29 2022-02-10 国立大学法人東北大学 シヌクレイノパチーを予防又は治療するために使用されるペプチド

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP2001521909A (ja) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド 糖タンパク質グリコフォームを含む方法及び組成物
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2180007B2 (en) 1998-04-20 2017-08-30 Roche Glycart AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236022A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
RU2326127C2 (ru) 2002-12-16 2008-06-10 Джинентех, Инк. Варианты иммуноглобулинов и их применение
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
ES2550311T3 (es) 2003-11-05 2015-11-06 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
EA013752B1 (ru) * 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
CN101052417A (zh) * 2004-08-09 2007-10-10 艾兰制药公司 突触核蛋白病以及淀粉样变性病的预防和治疗
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2657953A1 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007021255A1 (en) * 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
EP2325209A3 (en) * 2006-03-23 2011-08-03 BioArtic Neuroscience AB Improved protofibril selective antibodies and the use thereof
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
DK2068874T3 (da) * 2006-08-07 2015-04-27 Abbvie Biotherapeutics Inc Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
EP2051734B1 (en) 2006-08-18 2016-10-05 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
JP5558834B2 (ja) * 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP5291093B2 (ja) * 2007-05-16 2013-09-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド シヌクレイノパチーの治療
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
DK2949666T3 (en) * 2008-12-19 2019-03-25 Biogen Int Neuroscience Gmbh HUMAN ANTI-ALPHA SYNUCLEIN ANTIBODIES
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
KR20110126748A (ko) * 2009-04-07 2011-11-23 로슈 글리카트 아게 이중특이적 항-ｅｒｂｂ-1/항-ｃ-ｍｅｔ 항체
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
CN102448985B (zh) 2009-05-27 2015-08-05 霍夫曼-拉罗奇有限公司 三或四特异性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
WO2011057029A1 (en) * 2009-11-04 2011-05-12 Novartis Ag Positively charged species as binding reagents in the separation of protein aggregates from monomers
ES2661925T3 (es) 2010-02-26 2018-04-04 Bioarctic Ab Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías
US20130309690A1 (en) * 2010-11-05 2013-11-21 The Brigham And Women's Hospital, Inc. Tetrameric alpha-synuclein as biomarkers
LT2646470T (lt) 2010-11-30 2017-06-12 F. Hoffmann-La Roche Ag Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą
CN103502273A (zh) * 2011-04-20 2014-01-08 罗氏格黎卡特股份公司 用于pH依赖性通过血脑屏障的方法和构建体
EP2701743A4 (en) * 2011-04-27 2015-08-19 Univ Northwestern FOR PATHOLOGICAL TAU-DIMERE AND PREAFIBRILLARY PATHOLOGICAL TAU-OLIGOMER SELECTIVE ANTIBODIES AND THEIR USES IN THE APPLICATION, DIAGNOSIS AND MONITORING OF TAUOPATHIES
CN104619724B (zh) * 2012-01-27 2018-05-04 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
EP2890712B1 (en) * 2012-08-29 2019-05-01 F.Hoffmann-La Roche Ag Blood brain barrier shuttle
CA2927360C (en) 2013-10-25 2023-04-18 Nch Corporation Delivery system and probiotic composition for animals and plants
PL3089996T3 (pl) * 2014-01-03 2021-12-13 F. Hoffmann-La Roche Ag Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg

Also Published As

Publication number Publication date
AU2020200683A1 (en) 2020-02-20
EP3071597B1 (en) 2020-07-29
BR112016010065A2 (pt) 2017-12-05
US20180237510A1 (en) 2018-08-23
PT3071597T (pt) 2020-10-08
EP3783020A1 (en) 2021-02-24
US9493553B2 (en) 2016-11-15
US20150140003A1 (en) 2015-05-21
JP2022078255A (ja) 2022-05-24
RS60882B1 (sr) 2020-11-30
TW201609804A (zh) 2016-03-16
SI3071597T1 (sl) 2020-11-30
KR102399292B1 (ko) 2022-05-17
JP7074784B2 (ja) 2022-05-24
AU2014351996A1 (en) 2016-03-24
US20190292248A1 (en) 2019-09-26
IL244495B (en) 2020-06-30
KR102202925B1 (ko) 2021-01-14
EP3071597A1 (en) 2016-09-28
IL244495A0 (en) 2016-04-21
MX2016005631A (es) 2016-07-14
US9670274B2 (en) 2017-06-06
RU2718990C1 (ru) 2020-04-15
AR098465A1 (es) 2016-05-26
PL3071597T3 (pl) 2020-11-30
LT3071597T (lt) 2020-10-12
CN105722857A (zh) 2016-06-29
US9890209B2 (en) 2018-02-13
US20170327566A1 (en) 2017-11-16
CN111499743B (zh) 2024-01-12
KR20220019838A (ko) 2022-02-17
SG10202007189VA (en) 2020-09-29
AU2020200684A1 (en) 2020-02-20
CA2924268C (en) 2021-05-18
MY176237A (en) 2020-07-24
KR20160078998A (ko) 2016-07-05
AU2020200684B2 (en) 2021-04-22
RU2697098C1 (ru) 2019-08-12
JP2017504566A (ja) 2017-02-09
HK1220473A1 (zh) 2017-05-05
NZ717673A (en) 2020-02-28
US10647761B2 (en) 2020-05-12
CA2924268A1 (en) 2015-05-28
JP2020073565A (ja) 2020-05-14
CN111499742A (zh) 2020-08-07
AU2020200683B2 (en) 2021-04-22
CN105722857B (zh) 2023-03-24
CN111499742B (zh) 2024-05-07
CN111499743A (zh) 2020-08-07
US10316082B2 (en) 2019-06-11
HUE051982T2 (hu) 2021-04-28
WO2015075011A1 (en) 2015-05-28
HRP20201493T1 (hr) 2020-12-11
JP7367101B2 (ja) 2023-10-23
ES2821904T3 (es) 2021-04-28
MX2020002289A (es) 2020-07-13
US20170114123A1 (en) 2017-04-27
KR20210006509A (ko) 2021-01-18
AU2014351996B2 (en) 2020-01-02
RU2016124325A (ru) 2017-12-26
KR102358311B1 (ko) 2022-02-08

Similar Documents

Publication Publication Date Title
MX2020008436A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
MY191169A (en) Anti-fcrh5 antibodies
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX2020010141A (es) Anticuerpos anti-factor del complemento c1q y uso de los mismos.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MY193661A (en) Anti-tim3 antibodies and methods of use
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
PH12016501143A1 (en) Anti-cd33 antibodies and immunoconjugates
MX2015013901A (es) Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
MX2015010789A (es) Anticuerpos anti-pcsm.
NZ744340A (en) Anti-jagged1 antibodies and methods of use